Celia Larramendy - Publications
Affiliations: |
Year | Citation | Score | |||
---|---|---|---|---|---|
2015 | Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease. Neuropharmacology. PMID 25963416 DOI: 10.1016/J.Neuropharm.2015.04.018 | 0.651 | |||
2015 | Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, González GA, Fernández E, Murer MG, Gershanik OS. Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinson's disease Neuropharmacology. DOI: 10.1016/j.neuropharm.2015.04.018 | 0.64 | |||
2008 | Larramendy C, Taravini IR, Saborido MD, Ferrario JE, Murer MG, Gershanik OS. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. Behavioural Brain Research. 194: 44-51. PMID 18638507 DOI: 10.1016/J.Bbr.2008.06.021 | 0.624 | |||
2007 | Zold CL, Larramendy C, Riquelme LA, Murer MG. Distinct changes in evoked and resting globus pallidus activity in early and late Parkinson's disease experimental models. The European Journal of Neuroscience. 26: 1267-79. PMID 17767504 DOI: 10.1111/J.1460-9568.2007.05754.X | 0.417 | |||
2007 | Delfino M, Kalisch R, Czisch M, Larramendy C, Ricatti J, Taravini IR, Trenkwalder C, Murer MG, Auer DP, Gershanik OS. Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 32: 1911-21. PMID 17287822 DOI: 10.1038/Sj.Npp.1301329 | 0.704 | |||
Show low-probability matches. |